Non-cancer causes of death for patients with mycosis fungoides or Sézary syndrome from 2000 to 2020: a US population-based analysis of SEER patient data
In this US-based population analysis, non-cancer COD accounted for almost half of the deaths for patients diagnosed with MF or SS, and Cardiovascular Disease, usually preventable and treatable, was the leading non-cancer COD.
The findings reveal a distinctive malignancy profile characterized by a higher preva-lence of genitourinary, head, and neck, and gastrointestinal tumors compared to international co-horts, and an earlier average age of tumor onset highlighting unique regional characteristics.
Sarah Al Qassimi, R. Namas, W. Hafiz et al.· Current Rheumatology Reviews· 0 citations
Patients with STSs are at risk of developing a secondary malignancy, most commonly, prostate, breast, and melanoma and patients who are cured from their first malignancy should be followed indefinitely due to the risk of developing a second primary malignancy in the future.
Allison M. Nguyen-Thai, F. Amersi, Alexandra Gangi et al.· The American surgeon· 0 citations
BACKGROUND
Human herpesvirus 8 (HHV8), also known as Kaposi sarcoma (KS)-associated herpesvirus, can cause severe disease in liver transplant (LT) recipients, be donor-derived, and present variably. We describe HHV8 disease post-LT.
METHODS
HHV8 disease was identified post-LT in New South Wales (NSW), 2017-2024, and...
K. Waller, Sudarshan Arvind, S. Strasser et al.· Transplant Infectious Diseas...· 0 citations
OBJECTIVE
to evaluate malignant-transformation-free survival (MTFS) in patients with oral potentially malignant disorders (OPMDs).
MATERIAL AND METHODS
A 11-year long retrospective cohort study was conducted at a public Oral Pathology Service and patients diagnosed either with oral lichen planus, oral lichenoid lesio...
B. Ribeiro, A. Marinato, T. D. Deps et al.· Journal of Stomatology Oral...· 0 citations
Early immunologic evaluation and timely, individualized consideration of HSCT may support optimized management in children and adolescents, in whom cancer may be the first manifestation of IEI.
Nazli Deveci Demirbas, Z. Haskoloğlu, Tutku Baylan et al.· Frontiers in Immunology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.